Wednesday, July 8, 2026

Patent intelligence · US

US 11634688

Methods and compositions for inducing hematopoietic cell differentiation

granted A61PA61P37/02
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 17
Applicant portfolio 53
Patent details — US 11634688

Quick answer

US 11634688 (Methods and compositions for inducing hematopoietic cell differentiation) is held by Fate Therapeutics, Inc.. Status: granted. Granted Apr 25, 2023. Expires Apr 20, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
11
CPC classes
A61P, A61P37/02

More from Fate Therapeutics, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12419870

    Compositions and methods for immune cell modulation in adoptive immunotherapies

    Fate Therapeutics, Inc. · Expires Sep 18, 2045

    granted
  2. US 12410403

    Methods and compositions for inducing hematopoietic cell differentiation

    Fate Therapeutics, Inc. · Expires Sep 4, 2045

    granted
  3. US 12398373

    Enhanced immune effector cells and use thereof

    Fate Therapeutics, Inc. · Expires Aug 21, 2045

    granted
  4. US 12385012

    Methods and compositions for inducing hematopoietic cell differentiation

    Fate Therapeutics, Inc. · Expires Aug 7, 2045

    granted
  5. US 12281329

    Compositions and methods for immune cell modulation in adoptive immunotherapies

    Fate Therapeutics, Inc. · Expires Apr 17, 2045

    granted
  6. US 12275955

    Combining iPSC derived effector cell types for immunotherapy use

    Fate Therapeutics, Inc. · Expires Apr 10, 2045

    granted
  7. US 12264322

    Minimal volume reprogramming of mononuclear cells

    Fate Therapeutics, Inc. · Expires Mar 27, 2045

    granted
  8. US 12247226

    Cellular reprogramming using temporal and transient plasmid vector expression system

    Fate Therapeutics, Inc. · Expires Mar 6, 2045

    granted

Frequently asked questions

What is US patent 11634688?

US 11634688 (Methods and compositions for inducing hematopoietic cell differentiation) is held by Fate Therapeutics, Inc.. Status: granted. Granted Apr 25, 2023. Expires Apr 20, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11634688?

Fate Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 53 pharmaceutical patents for this assignee.

When does US 11634688 expire?

Our index shows an expiration date of Apr 20, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.